Hello, my name is Peter Galle, from the University Medical Center in Mainz, Germany. Last year, a multidisciplinary team of experts convened to discuss the impact of the IMbrave150 trial, assessing the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.
This resulted in a position paper, where we discuss the important aspects of the trial with respect to efficacy, safety, and the impact on scheduling of systemic therapy in hepatocellular carcinoma.
We are now at a situation where we have seen a timely update of the data from 2020, which appeared at the ASCO GI meeting in January 2021 in San Francisco. It was good to see that the improvement of overall survival (OS) was not only confirmed, but now it was actually given in absolute numbers: we see a six-month improvement in overall survival comparing atezo + bev versus sorafenib.
This has resulted in the meantime in the approval of this combination in more than 160 countries worldwide, for the benefit of our patients. Thank you for your interest.